Study on influence of atrial fibrillation on prognosis of acute ischemic stroke treated with thrombolytic therapy

CHEN Miao,ZHU Jingfen,LIU Ming,LIU Jiafu,JIANG Shaowei,WANG Hairong,PAN Shuming

DOI: https://doi.org/10.3969/j.issn.1673-6087.2013.05.007

2013-01-01

Abstract:Objective To investigate the influence of atrial fibrillation(AF) on prognosis of acute ischemic stroke(AIS) treated with recombinant tissue plasminogen activator(rtPA) thrombolytic therapy. Methods All of the AIS patients diagnosed in accordance with the Chinese guideline on the prevention and treatment of cerebrovascular disease and admitted from June, 2010 to September, 2012 were enrolled. Patients were divided into two groups according to the electrocardiogram whether there was auricular fibrillation(AF) or not(group AF, group non-AF). All patients were treated with rtPA and other neuroprotectants recommended by the guideline. The National Institute of Health stroke scale(NIHSS)score on the acute attack, NIHSS score 24 h after thrombolysis, and modified Rankin scale(mRS) score, morbidity of symptomatic intracerebral hemorrhage(sICH) and mortality within three months were recorded. Results One hundred and fourteen patients were enrolled. There were statistically significant differences between patients with and without AF on age and sex ratio(all P<0.05). The NIHSS immediately on hospitalization for patients with AF was 11.0±7.5, while that for patients without AF was 7.0±6.0(P=0.004). However, no significant differences in NIHSS was seen 24 h after thrombolysis(P =0.123). The morbidity of sICH in patients with AF was 43.3%, while that without AF was 17.9%(P =0.005). No significant differences were found in mRS score and 3-month mortality between the two groups. Conclusions The recovery of neurological function 24 h after rtPA thrombolytic therapy and three months later in AIS patients with AF was similar to that without AF. However, the morbidity of sICH was significantly higher. The emergency physician needs to take judicious consideration for the use of thrombolytic therapy in patients of AIS with AF.